| KAI Pharmaceuticals Announces Phase 1 Results of KAI-4169 for the Treatment of ... - Lifescience-online |
|
|
Lifescience-onlineKAI plans to begin recruitment in a Phase 1b study in patients with ESRD and SHPT this quarter. Steven James, President and CEO of KAI, commented, ? ... read more |